ARWRArrowhead Pharmaceuticals, Inc.
What is the market doing?
No clear lean: rangebound and insiders net selling (often routine).
Rangebound, no clear trend. Price is −12% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Moderately shorted, settled Sep 15, 2026, about a week of normal trading to cover. Down 1.6% since the previous count, down from 8.2% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How ARWR is trading
Arrowhead Pharmaceuticals, Inc. is +105% over the past year while the S&P 500 is +18%: 86 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −12%
vs 200-day average · a clear downtrend
- RSI (14)
- 33
RSI (14) · neutral
- Below its 52-week high
- 30%
Below its 52-week high
Details›
- Last close2026-10-09
- $62.78
- 1 monthS&P 500 +2.7%
- −24%
- 1 yearS&P 500 +18%
- +105%
- 5 yearsS&P 500 +88%
- +0.42%
- vs 50-day average$78.35
- −20%
- 52-week high
- $89.61
- 52-week low
- $31.66
- Annualised volatility
- 67%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$1.2M
| Year | Return |
|---|---|
| 2026 (year to date) | −5.4% |
| 2025 | +253% |
| 2024 | −39% |
| 2023 | −25% |
| 2022 | −39% |
| 2021 | −14% |
| 2020 | +21% |
| 2019 | +411% |
| 2018 | +237% |
| 2017 | +137% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 7 of 10 | +5.4% |
| Feb | 10 | 4 of 10 | +0.93% |
| Mar | 10 | 2 of 10 | −11% |
| Apr | 10 | 5 of 10 | +3.4% |
| May | 10 | 5 of 10 | +8.7% |
| Jun | 10 | 9 of 10 | +12% |
| Jul | 11 | 7 of 11 | +5.1% |
| Aug | 11 | 5 of 11 | +7.4% |
| Sep | 11 | 5 of 11 | +6.0% |
| Oct | 11 | 5 of 11 | +2.0% |
| Nov | 10 | 6 of 10 | +7.7% |
| Dec | 10 | 6 of 10 | +6.9% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.